Administration of amantadine for the prevention of Hong Kong influenza.
The prophylactic effectiveness of amantadine against A2/Hong Kong influenza was investigated in the course of a double-blind trial in Braşov, Romania, during an epidemic due to the Hong Kong virus that started there in March 1969.Altogether 215 subjects were included in the trial; 112 received 100 mg of amantadine twice daily for 20 days and the remaining 103 received inert placebo tablets. Of the amantadine-treated group, 2 had clinical symptoms diagnosed as influenza (1 of these was a doubtful diagnosis), whereas 20 (1 doubtful) of the placebo group had such symptoms. No case with both clinical symptoms and serologically confirmed influenza (>/=4-fold increase in haemagglutination-inhibition titre) occurred among 77 amantadine-treated subjects for whom paired sera were available but there were 13 such cases among the 74 placebo subjects with paired sera. These differences are statistically highly significant. No serious side-effects were recorded.The authors conclude that amantadine was highly effective in preventing overt disease and discuss indications that suggest that it did not interfere with the development of immunity in persons treated during the incubation period.
D000293:Adolescent; D000328:Adult; D000547:Amantadine / Q000627:therapeutic use*; D000906:Antibodies; D002648:Child; D004196:Disease Outbreaks; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D008875:Middle Aged; D010919:Placebos; D012383:Romania
D000906:Antibodies; D010919:Placebos; D000547:Amantadine